SRB
Sailesh Raj BhanFund Manager Since 1 Apr 2005
EquitySector - Healthcare
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl
3Y Annualised
22.09%
0.09% 1D
Fund Performance
Fund Multiplier
Fund Info
Peer Comparison
Fund Managers
AMC Details
Performance
1M Returns
-0.39%
0.09% 1D
Benchmark
N/A
Fund Multiplier
Time it would have taken to make your money double (2x), quadruple (4x) and quintuple (5x)
This Fund
3 years 6 months
NIFTY 50
5 years 8 months
FD
9 years 7 months
Fund info
Fund size
₹8458.68 Cr
Min. SIP amount
₹100
Min. Lumpsum amount
₹5000
Exit load
0.01%
1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units. Nil, thereafter.
Risk Profile
Very High Risk
Peer Comparison
This Fund's Performance Compared With Peers
Over the Period of oneMonth
1st
Nippon India Nifty Pharma ETF
0.94%
2nd
Axis NIFTY Healthcare ETF
-0.21%
3rd
Nippon India Pharma Fund - Direct Plan - Growth Plan
-0.39%
4th
Nippon India Pharma Fund - Direct Plan - Bonus Plan
-0.39%
5th
Nippon India Pharma Fund Direct Plan Payout Inc Dist cum Cap Wdrl
-0.39%
6th
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl
-0.39%
Fund Managers
KD
Kinjal DesaiFund Manager Since 25 May 2018
About Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl is a Equity mutual fund scheme from Nippon Life India Asset Management Ltd. This fund has been in existence for 12 years, having been launched on 2013-01-01. Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl has ₹8458.68 Cr worth of assets under management (AUM) as of Tue Dec 16 2025. The latest Net Asset Value (NAV) of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl as of Mon Dec 15 2025 is ₹168.6945. The fund has an expense ratio of 0.91%, which is medium comparable to most other Equity funds.
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl returns for the last 1 year are 0.46%. Since launch, it has delivered 18.87% average annual returns.
The Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl has the majority of its money invested in Healthcare sectors.
Top 5 Holdings of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl.
- Sun Pharmaceuticals Industries Ltd: 13.55%
- Lupin Ltd: 7.59%
- Divi's Laboratories Ltd: 6.90%
- Cipla Ltd: 6.33%
- Dr Reddy's Laboratories Ltd: 5.83%
AMC Information
| Name | Nippon Life India Asset Management Ltd |
|---|---|
| Founding Date | 2013-01-01 |
| customercare@nipponindiaim.in | |
| Phone | 022-6808 7000/18602660111 |
| Website | https://mf.nipponindiaim.com/ |
| Address | Nippon Life India Asset Management Limited,4th Floor, Tower A, Peninsula Business Park,,Ganapatrao Kadam Marg,,Lower Parel (W) |
Tax Implications of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl
| Short Term Gains | 20% + applicable Surcharge + 4% Cess |
|---|---|
| Long Term Gains | 12.5% without indexation + applicable Surcharge + 4% Cess |
Similar Funds from Nippon Life India Asset Management Ltd
Nippon India Aggressive Hybrid Fund - Direct Plan - Growth Option
AllocationAggressive Allocation
3Y CAGR
15.62%
expense ratio
1.08%
fund size
₹4133.57 Cr
Nippon India ELSS Tax Saver Fund Direct Plan - Growth Option
EquityELSS (Tax Savings)
3Y CAGR
17.16%
expense ratio
1.02%
fund size
₹15519.07 Cr
Nippon India Multi Cap Fund - Direct Plan - Growth
EquityMulti-Cap
3Y CAGR
21.91%
expense ratio
0.71%
fund size
₹50048.30 Cr
Nippon India Equity Savings Direct Growth
AllocationEquity Savings
3Y CAGR
9.60%
expense ratio
0.74%
fund size
₹945.01 Cr
Nippon India Equity Savings Growth
AllocationEquity Savings
3Y CAGR
8.56%
expense ratio
1.79%
fund size
₹945.01 Cr
Calculate Your Returns
Estimated Returns in 3 Years (Based on past 3Y returns)
₹0
Total Amount
₹0
